Schrödinger Reports Second Quarter 2022 Financial Results
Software Revenue of $30.0 Million, a 25 Percent Increase Over Second Quarter of 2021; Total Revenue of $38.5 Million, up 29 Percent Over Second Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Phase 1 Clinical Study of SGR-1505, Schrödinger’s MALT1 Inhibitor, On-Track to Begin in the Fourth Quarter of 2022 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. … [Read more…]
